ATE256123T1 - Pyrimidonderivate - Google Patents

Pyrimidonderivate

Info

Publication number
ATE256123T1
ATE256123T1 AT99944815T AT99944815T ATE256123T1 AT E256123 T1 ATE256123 T1 AT E256123T1 AT 99944815 T AT99944815 T AT 99944815T AT 99944815 T AT99944815 T AT 99944815T AT E256123 T1 ATE256123 T1 AT E256123T1
Authority
AT
Austria
Prior art keywords
pyrimidone derivatives
pyrimidone
derivatives
Prior art date
Application number
AT99944815T
Other languages
English (en)
Inventor
Kazutoshi Watanabe
Ryoichi Ando
Ken-Ichi Saito
Rie Kawamoto
Aya Shoda
Original Assignee
Mitsubishi Chem Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mitsubishi Chem Corp filed Critical Mitsubishi Chem Corp
Application granted granted Critical
Publication of ATE256123T1 publication Critical patent/ATE256123T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
AT99944815T 1998-09-25 1999-09-24 Pyrimidonderivate ATE256123T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP27127798 1998-09-25
JP30526698 1998-10-27
PCT/JP1999/005224 WO2000018758A1 (en) 1998-09-25 1999-09-24 Pyrimidone derivatives

Publications (1)

Publication Number Publication Date
ATE256123T1 true ATE256123T1 (de) 2003-12-15

Family

ID=26549626

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99944815T ATE256123T1 (de) 1998-09-25 1999-09-24 Pyrimidonderivate

Country Status (16)

Country Link
US (1) US7256199B1 (de)
EP (1) EP1115721B1 (de)
JP (1) JP2002525366A (de)
KR (1) KR20010087362A (de)
CN (1) CN1328552A (de)
AR (1) AR023052A1 (de)
AT (1) ATE256123T1 (de)
AU (1) AU5759999A (de)
CA (1) CA2345065A1 (de)
CO (1) CO5180553A1 (de)
DE (1) DE69913545T2 (de)
DK (1) DK1115721T3 (de)
ES (1) ES2214045T3 (de)
PT (1) PT1115721E (de)
TW (1) TWI241298B (de)
WO (1) WO2000018758A1 (de)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1136482A1 (de) 2000-03-23 2001-09-26 Sanofi-Synthelabo 2-Amino-3-(alkyl)-pyrimidonderivate als GSK3beta-Hemmer
AU2001262150A1 (en) * 2000-03-23 2001-10-03 Mitsubishi Pharma Corporation 2-(nitrogen-heterocyclic)pyrimidone derivatives
JP2005289808A (ja) * 2000-03-23 2005-10-20 Sanofi-Aventis ３−置換−４−ピリミドン誘導体
EP1136486A1 (de) * 2000-03-23 2001-09-26 Sanofi-Synthelabo 2-(Indanylamino)pyrimidon und 2-(Tetrahydronaphtalenylamino)pyrimidinon Derivate
AU5260601A (en) 2000-04-26 2001-11-07 Eisai Co Ltd Medicinal compositions promoting bowel movement
EP1184385A1 (de) * 2000-09-01 2002-03-06 Sanofi-Synthelabo 1-[Alkyl], 1-[(Heteroaryl)alkyl] und 1[(Aryl)alkyl]-7-pyridin-4-yl-2,3-dihydroimidazo[1,2-a]pyrimidin-5(1H)-on Derivate
EP1184384A1 (de) * 2000-09-01 2002-03-06 Sanofi-Synthelabo 1-Alkyl, 1-(Heteroaryl)alkyl und 1-(Aryl)alkyl-7-pyridin-4-ylimidazo[1,2-a]pyrimidin-5(1H)-on Derivate
EP1184383A1 (de) * 2000-09-01 2002-03-06 Sanofi-Synthelabo 9-[Alkyl], 9-[(Heteroaryl)alkyl] und 9-[(Aryl)alkyl]-2-pyridinyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-on Derivate
AR030587A1 (es) 2000-09-01 2003-08-27 Sanofi Aventis Derivados de 2-piridinil-6,7,8,9-tetrahidropirimido[1,2-a]pirimidin-4-ona y 7-piridinil-2,3-dihidroimidazo[1,2-a]pirimidin-5(1h)-ona
CA2457965C (en) * 2001-09-21 2010-06-01 Sanofi-Synthelabo Substituted 2-pyridinyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one and 7-pyridinyl-2,3-dihydroimidazo[1,2-a]pyrimidin-5(1h)one derivatives
IL160701A0 (en) * 2001-09-21 2004-08-31 Mitsubishi Pharma Corp 3-substituted-4-pyrimidone derivatives
EP1295885A1 (de) * 2001-09-21 2003-03-26 Sanofi-Synthelabo Substituierte 2-pyridinyl-6,7,8,9-tetrahydropyrimido(1,2-a)pyrimidin-4-on- und 7-pyridinyl-2,3-dihydroimidazo(1,2-a)pyrimidin-5(1H)onderivate
CN101274928A (zh) * 2001-09-21 2008-10-01 三菱制药株式会社 3-取代的-4-嘧啶酮衍生物
EP1340760A1 (de) * 2002-02-28 2003-09-03 Sanofi-Synthelabo Substituierte 2-Pyrimidinyl-6,7,8,9-tetrahydro[1,2-a]pyrimidin-4-on und 7-Pyrimidinyl-2,3-dihydroimidazo[1,2-a]pyrimidin-5(1H)onderivate
EP1340761A1 (de) * 2002-02-28 2003-09-03 Sanofi-Synthelabo Substituierte 2-Pyridinyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-on und 7-Pyridinyl-2,3-dihydroimidazo[1,2-a]pyrimidin-5(1H)onderivate
IL160700A0 (en) 2001-09-21 2004-08-31 Mitsubishi Pharma Corp 3-substituted-4-pyrimidone derivatives
TWI330183B (de) 2001-10-22 2010-09-11 Eisai R&D Man Co Ltd
TWI301834B (en) 2001-10-22 2008-10-11 Eisai R&D Man Co Ltd Pyrimidone compound and pharmaceutical composition including the same
AR038368A1 (es) 2002-02-01 2005-01-12 Novartis Ag Compuestos n-pirimidin-2-il-aminas sustituidas como inhibidores de ige, una composicion farmaceutica y el uso de dichos compuestos para la preparacion de un medicamento
EP1340759A1 (de) 2002-02-28 2003-09-03 Sanofi-Synthelabo 1-Alkyl, 1-(Heteroaryl)alkyl und 1-(Aryl)alkyl-7-pyrimidin-4-ylimidazo[1,2-a]pyrimidin-5(1H)-on Derivate
EP1348708A1 (de) * 2002-02-28 2003-10-01 Sanofi-Synthelabo Heteroarylsubstituierte 2-Pyrimidinyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-on und 7-Pyrimidinyl-2,3-dihydroimidazo[1,2-a]pyrimidin-5(1H)onderivate
DE60302221T2 (de) 2002-02-28 2006-08-03 Sanofi-Aventis Heteroaryl substituierte 2-pyridinyl und 2-pyrimidinyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-onderivate
EP1340758A1 (de) * 2002-02-28 2003-09-03 Sanofi-Synthelabo Heteroarylsubstituierte 2-Pyridinyl-6,7,8,9-tetrahydro[1,2-a]pyridin-4-on und 7-Pyridinyl-2,3-dihydroimidazo[1,2-a]pyrimidin-5(1H)onderivate
DE10238722A1 (de) 2002-08-23 2004-03-11 Bayer Ag Selektive Phosphodiesterase 9A-Inhibitoren als Arzneimittel zur Verbesserung kognitiver Prozesse
CN1726209B (zh) 2002-12-16 2011-04-13 三菱制药株式会社 3-取代的-4-嘧啶酮衍生物
TWI357408B (en) 2003-03-26 2012-02-01 Mitsubishi Tanabe Pharma Corp 3-substituted-4-pyrimidone derivatives
DE10320785A1 (de) 2003-05-09 2004-11-25 Bayer Healthcare Ag 6-Arylmethyl-substituierte Pyrazolopyrimidine
DE10328479A1 (de) 2003-06-25 2005-01-13 Bayer Ag 6-Arylamino-5-cyano-4-pyrimidinone
DE102004001873A1 (de) * 2004-01-14 2005-09-29 Bayer Healthcare Ag Cyanopyrimidinone
US20070117818A1 (en) * 2004-02-04 2007-05-24 Masaichi Hasegawa Pyrimidinone compounds useful as kinase inhibitors
AR050865A1 (es) 2004-09-09 2006-11-29 Sanofi Aventis Derivados de 2- morfolino-4-pirimidona
CN101048397A (zh) 2004-09-29 2007-10-03 三菱制药株式会社 作为τ蛋白激酶1抑制剂的6－（吡啶基）－4－嘧啶酮衍生物
JP2008516945A (ja) * 2004-10-15 2008-05-22 アストラゼネカ・アクチエボラーグ 置換されたアミノ化合物およびそれらの使用
EP1802588A4 (de) * 2004-10-15 2010-02-17 Astrazeneca Ab Substituierte aminopyrimidone und anwendungen davon
EP2275095A3 (de) 2005-08-26 2011-08-17 Braincells, Inc. Neurogenese durch modulation des Muscarinrezeptors
EP2258358A3 (de) 2005-08-26 2011-09-07 Braincells, Inc. Neurogenese mit Acetylcholinesterasehemmer
EP1940389A2 (de) 2005-10-21 2008-07-09 Braincells, Inc. Modulation von neurogenese durch pde-hemmung
AU2006308889A1 (en) 2005-10-31 2007-05-10 Braincells, Inc. GABA receptor mediated modulation of neurogenesis
EP1951680A4 (de) * 2005-11-15 2011-08-10 Astrazeneca Ab Neue 2-aminopyrimidonderivate und deren verwendung
CN101360721A (zh) * 2005-11-15 2009-02-04 阿斯利康(瑞典)有限公司 新颖的2-氨基嘧啶酮衍生物或2-氨基吡啶酮衍生物及其用途
JP2009515950A (ja) * 2005-11-15 2009-04-16 アストラゼネカ・アクチエボラーグ 新規な２−アミノピリミジン誘導体およびその使用
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
TW200813015A (en) * 2006-03-15 2008-03-16 Mitsubishi Pharma Corp 2-(cyclic amino)-pyrimidone derivatives
CN101460480A (zh) * 2006-04-05 2009-06-17 阿斯利康(瑞典)有限公司 2-氨基嘧啶-4-酮类化合物及其用于治疗或预防Aβ相关病理的用途
EP2382975A3 (de) 2006-05-09 2012-02-29 Braincells, Inc. Neurogenese mittels Angiotensin-Modulation
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
AR064660A1 (es) * 2006-12-26 2009-04-15 Mitsubishi Tanabe Pharma Corp Derivados de pirimidinona 6-heterociclica 2-sustituida, medicamentos que los contienen y usos para prevenir y/o tratar enfermedades neurodegenerativas entre otras
EP1992624A1 (de) * 2007-05-16 2008-11-19 Sanofi-Aventis Heteroarylamid-Pyrimidon-Verbindungen
EP1992625A1 (de) * 2007-05-16 2008-11-19 Sanofi-Aventis Arylamid-Pyrimidon-Verbindungen
EP1992621A1 (de) 2007-05-16 2008-11-19 Sanofi-Aventis Heteroarylamid-substituierte Pyrimidon-Derivate zur Behandlung von neurodegenerativen Krankheiten
WO2009066084A1 (en) * 2007-11-21 2009-05-28 F. Hoffmann-La Roche Ag 2 -morpholinopyrimidines and their use as pi3 kinase inhibitors
JP5498392B2 (ja) 2007-11-30 2014-05-21 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング １，５−ジヒドロ−ピラゾロ［３，４−ｄ］ピリミジン−４−オン誘導体及びｃｎｓ障害の治療のためのｐｄｅ９ａモジュレーターとしてのそれらの使用
UA105362C2 (en) 2008-04-02 2014-05-12 Бьорингер Ингельхайм Интернациональ Гмбх 1-heterocyclyl-1, 5-dihydro-pyrazolo [3, 4-d] pyrimidin-4-one derivatives and their use as pde9a modulators
KR20110063447A (ko) 2008-09-08 2011-06-10 베링거 인겔하임 인터내셔날 게엠베하 피라졸로피리미딘 및 ｃｎｓ 장애의 치료를 위한 이들의 용도
WO2010099217A1 (en) 2009-02-25 2010-09-02 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
PT2414363E (pt) 2009-03-31 2014-02-26 Boehringer Ingelheim Int Derivados de 1-heterociclil-1,5-di-hidro-pirazolo[3,4- d]pirimidin-4-ona e sua utilização como moduladores de pde9a
AR076014A1 (es) 2009-04-02 2011-05-11 Sanofi Aventis Derivados de 3- (1,4) oxazepan -4-pirimidona
SG10201402867TA (en) * 2009-07-02 2014-08-28 Sanofi Sa Novel (6-oxo-1, 6-dihydro-pyrimidin-2-yl)-amide derivatives, preparation thereof, and pharmaceutical use thereof as akt(pkb) phosphorylation inhibitors
WO2011019090A1 (en) * 2009-08-13 2011-02-17 Mitsubishi Tanabe Pharma Corporation Pyrimidone derivatives used as tau protein kinase 1 inhibitors
EP2603511B1 (de) 2010-08-12 2017-03-15 Boehringer Ingelheim International GmbH 6-cycloalkyl-1, 5-dihydro-pyrazolo [3, 4-d] pyrimidin-4-on derivate und ihre verwendung als pde9a inhibitoren
US8809345B2 (en) 2011-02-15 2014-08-19 Boehringer Ingelheim International Gmbh 6-cycloalkyl-pyrazolopyrimidinones for the treatment of CNS disorders
WO2016145614A1 (en) 2015-03-17 2016-09-22 Merck Sharp & Dohme Corp. Triazolyl pyrimidinone compounds as pde2 inhibitors
WO2016179059A1 (en) * 2015-05-05 2016-11-10 Merck Sharp & Dohme Corp. Heteroaryl-pyrimidinone compounds as pde2 inhibitors

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS559099B2 (de) 1972-08-07 1980-03-07
JPS4935633A (de) 1972-08-09 1974-04-02
JPS5124008B2 (de) 1972-08-10 1976-07-21
JPS4935632A (de) 1972-08-10 1974-04-02
JPS5271481A (en) 1975-12-10 1977-06-14 Yoshitomi Pharmaceut Ind Ltd Synthesis of pyridylpyrimidines
JPS52139085A (en) 1976-05-13 1977-11-19 Hokuriku Pharmaceutical 22allylpiperazine derivative and method for its preparation
US4507302A (en) * 1979-03-19 1985-03-26 The Upjohn Company Method for treating arthritis with 6-aryl pyrimidine compounds
US4619933A (en) * 1979-09-28 1986-10-28 The Upjohn Company 6-aryl pyrimidines for treating aplastic anemia
US4725600A (en) * 1984-07-13 1988-02-16 Fujisawa Pharmaceutical Co., Ltd. Pyrimidine compounds having activity as a cardiotonic anti-hypertensive cerebrovascular vasodilator and anti-platelet aggregation agent
DE58908208D1 (de) 1988-07-29 1994-09-22 Ciba Geigy Ag Thiouracile als Stabilisatoren für chlorhaltige Polymerisate.
DK0618968T3 (da) 1991-12-06 2000-04-10 Max Planck Gesellschaft Midler til diagnostisering og behandling af Alzheimer's sygdom
DE4206145A1 (de) 1992-02-28 1993-09-02 Basf Ag Herbizide n-((pyrimidin-2-yl)aminocarbonyl)benzolfulfonamide
JP3324611B2 (ja) 1992-07-03 2002-09-17 三菱化学株式会社 タウ蛋白質のリン酸化方法
JPH06329551A (ja) 1993-03-22 1994-11-29 Mitsubishi Kasei Corp アルツハイマー病の予防または治療薬およびそのスクリーニング方法
BR9407799A (pt) * 1993-10-12 1997-05-06 Du Pont Merck Pharma Composição de matéria método de tratamento e composição farmaceutica
US6410729B1 (en) * 1996-12-05 2002-06-25 Amgen Inc. Substituted pyrimidine compounds and methods of use
US6096753A (en) 1996-12-05 2000-08-01 Amgen Inc. Substituted pyrimidinone and pyridone compounds and methods of use
EP0948496A2 (de) * 1996-12-05 1999-10-13 Amgen inc. Subsituierte pyrimidinon- und pyridinon-verbindungen und ihre verbindung
TW520362B (en) 1996-12-05 2003-02-11 Amgen Inc Substituted pyrimidine compounds and pharmaceutical composition comprising same
WO2001062233A2 (en) * 2000-02-25 2001-08-30 F. Hoffmann La Roche Ag Adenosine receptor modulators
AU2001262150A1 (en) 2000-03-23 2001-10-03 Mitsubishi Pharma Corporation 2-(nitrogen-heterocyclic)pyrimidone derivatives
EP1136482A1 (de) * 2000-03-23 2001-09-26 Sanofi-Synthelabo 2-Amino-3-(alkyl)-pyrimidonderivate als GSK3beta-Hemmer
IL160701A0 (en) 2001-09-21 2004-08-31 Mitsubishi Pharma Corp 3-substituted-4-pyrimidone derivatives
IL160700A0 (en) 2001-09-21 2004-08-31 Mitsubishi Pharma Corp 3-substituted-4-pyrimidone derivatives
CN1726209B (zh) 2002-12-16 2011-04-13 三菱制药株式会社 3-取代的-4-嘧啶酮衍生物
TWI357408B (en) 2003-03-26 2012-02-01 Mitsubishi Tanabe Pharma Corp 3-substituted-4-pyrimidone derivatives

Also Published As

Publication number Publication date
EP1115721A1 (de) 2001-07-18
DE69913545D1 (en) 2004-01-22
TWI241298B (en) 2005-10-11
CA2345065A1 (en) 2000-04-06
DK1115721T3 (da) 2004-04-19
EP1115721B1 (de) 2003-12-10
CO5180553A1 (es) 2002-07-30
AR023052A1 (es) 2002-09-04
AU5759999A (en) 2000-04-17
WO2000018758A1 (en) 2000-04-06
PT1115721E (pt) 2004-04-30
KR20010087362A (ko) 2001-09-15
DE69913545T2 (de) 2004-09-16
ES2214045T3 (es) 2004-09-01
CN1328552A (zh) 2001-12-26
JP2002525366A (ja) 2002-08-13
US7256199B1 (en) 2007-08-14

Similar Documents

Publication Publication Date Title
ATE256123T1 (de) Pyrimidonderivate
NO20010193D0 (no) Tiobenzimidazol-derivater
DK0930302T3 (da) Benzosulfonderivater
NO20010514D0 (no) Aminometylkarboksylsyre-derivater
ATE293104T1 (de) Thiazolylamid-derivate
ATE263748T1 (de) Admantan-derivate
ATE259810T1 (de) Phenyl-xanthinderivate
ATE277941T1 (de) Adenosinderivate
PT928790E (pt) Derivados de tiazolo
ATE257148T1 (de) Propargyletherderivate
DE69930543D1 (de) Piperazin-derivate
PT1154988E (pt) Derivados de mevinolina
ATE374747T1 (de) Monofluoralkylderivate
ATE293592T1 (de) Resorcinderivate
PT1187815E (pt) Derivados de 4-fenil-pirimidina
ATE254598T1 (de) 4-hydroxybiphenylhydrazid-derivate
DK1115716T3 (da) 2-phenylpyran-4-on-derivater
PT1056716E (pt) Derivados de ciclo-hexanodiolo
DE69524611D1 (de) Pyrimidon-derivate
ATE233253T1 (de) Chromanderivate
DK1134219T3 (da) Cucloalkylsubstituerede aminomethylpyrrolidinderivater
PT1088818E (pt) Derivados de quinolin-4-ilo
DK1060183T3 (da) 5-deoxycytidinderivater
PT1194401E (pt) Derivados de diacil-hidrazina
PT1123283E (pt) Derivados de tiazole

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1115721

Country of ref document: EP